Nalbuphine for Cough Caused by Idiopathic Pulmonary Fibrosis

The CORAL trial suggests that nalbuphine ER may be a promising treatment for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), a severe lung disease. The study found that nalbuphine was highly effective in managing cough symptoms, which are a significant source of discomfort and reduced quality of life for those affected by IPF. This development is crucial as there are limited effective treatments for cough related to IPF, highlighting the potential importance of nalbuphine as a new therapeutic option. The findings could pave the way for better management of symptoms and improved patient outcomes.